- Home
- SYRE vs FDS Comparison
SYRE vs FDS Comparison
Compare SYRE & FDS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SYRE | FDS |
|---|---|---|
| Founded | 2013 | 1978 |
| Country | United States | United States |
| Employees | N/A | 6258 |
| Industry | Biotechnology: Pharmaceutical Preparations | Computer Software: Programming Data Processing |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 8.5B | 9.1B |
| IPO Year | 2015 | 1996 |
Fundamental Metrics
Financial Performance| Metric | SYRE | FDS |
|---|---|---|
| Price | $107.33 | $297.93 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 12 | 11 |
| Target Price | $85.08 | ★ $284.80 |
| AVG Volume (30 Days) | ★ 794.3K | 726.1K |
| Earning Date | 05-08-2026 | 03-31-2026 |
| Dividend Yield | N/A | ★ 1.89% |
| EPS Growth | N/A | ★ 11.79 |
| EPS | N/A | ★ 11.16 |
| Revenue | N/A | ★ $1,435,351,000.00 |
| Revenue This Year | N/A | $7.16 |
| Revenue Next Year | N/A | $5.55 |
| P/E Ratio | ★ N/A | $27.36 |
| Revenue Growth | N/A | ★ 6.31 |
| 52 Week Low | $14.51 | $185.00 |
| 52 Week High | $110.18 | $384.33 |
Technical Indicators
Market Signals| Indicator | SYRE | FDS |
|---|---|---|
| Relative Strength Index (RSI) | 60.88 | 63.17 |
| Support Level | $93.45 | $267.36 |
| Resistance Level | N/A | $300.77 |
| Average True Range (ATR) | 4.53 | 9.47 |
| MACD | -0.09 | 1.14 |
| Stochastic Oscillator | 87.74 | 75.79 |
Price Performance
Historical ComparisonAbout SYRE Spyre Therapeutics Inc.
Spyre Therapeutics Inc is a clinical-stage biotechnology company pioneering long-acting antibodies and antibody combinations to redefine the standard of care for inflammatory bowel disease (IBD) and rheumatic diseases. Spyre's pipeline includes extended half-life antibodies targeting α4β7, TL1A, and IL-23 in development as monotherapies and pair-wise combinations. It has a single reportable segment, which is the development of biopharmaceutical products for the treatment of patients with IBD and other immune-mediated disease.
About FDS FactSet Research Systems Inc.
FactSet provides financial data and portfolio analytics to the global investment community. The company aggregates data from third-party data suppliers, news sources, exchanges, brokerages, and contributors into its workstations. In addition, it provides essential portfolio analytics that companies use to monitor portfolios and address reporting requirements. Buy-side clients (including wealth and corporate clients) account for over 80% of FactSet's annual subscription value. In 2015, the company acquired Portware, a provider of trade execution software. In 2017, it acquired BISAM, a risk management and performance measurement provider. In 2022, it completed its purchase of CUSIP Global Services.